PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Given Consensus Recommendation of “Hold” by Brokerages

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) has earned an average recommendation of “Hold” from the sixteen research firms that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, ten have given a hold recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $28.00.

PRCT has been the topic of several recent analyst reports. Citigroup downgraded PROCEPT BioRobotics to a “hold” rating in a research report on Thursday, July 2nd. UBS Group downgraded shares of PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 target price for the company. in a report on Tuesday, July 28th. Piper Sandler dropped their price target on shares of PROCEPT BioRobotics from $35.00 to $25.00 and set an “overweight” rating for the company in a research report on Wednesday, August 5th. Jefferies Financial Group reaffirmed a “hold” rating and set a $20.00 price target on shares of PROCEPT BioRobotics in a research note on Wednesday, August 5th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Friday, July 17th.

Insider Activity at PROCEPT BioRobotics

In other news, CEO Larry L. Wood acquired 23,900 shares of PROCEPT BioRobotics stock in a transaction dated Friday, August 7th. The shares were acquired at an average cost of $20.85 per share, with a total value of $498,315.00. Following the purchase, the chief executive officer directly owned 23,900 shares of the company’s stock, valued at approximately $498,315. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders sold 1,000 shares of company stock valued at $28,480. Company insiders own 4.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new position in shares of PROCEPT BioRobotics in the 2nd quarter valued at $109,961,000. California State Teachers Retirement System boosted its position in PROCEPT BioRobotics by 2,104.3% during the 2nd quarter. California State Teachers Retirement System now owns 1,547,069 shares of the company’s stock worth $34,933,000 after purchasing an additional 1,476,885 shares during the period. Prosight Management LP boosted its position in PROCEPT BioRobotics by 1,692.4% during the 4th quarter. Prosight Management LP now owns 1,380,000 shares of the company’s stock worth $43,415,000 after purchasing an additional 1,303,009 shares during the period. Alliancebernstein L.P. increased its holdings in PROCEPT BioRobotics by 58.6% in the 3rd quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock valued at $122,052,000 after purchasing an additional 1,262,928 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. raised its position in PROCEPT BioRobotics by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock valued at $102,919,000 after purchasing an additional 1,218,815 shares during the period. Hedge funds and other institutional investors own 89.46% of the company’s stock.

Key PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Several law firms, including Hagens Berman, Rosen, Kaplan Fox, Pomerantz, and others, are soliciting investors who purchased PRCT securities between February 28, 2024, and February 25, 2026. Investors have until September 22, 2026, to seek appointment as lead plaintiff. Hagens Berman class-action announcement
• Negative Sentiment: The underlying lawsuit alleges that PROCEPT misled investors about demand and recurring sales trends by using repeated late-quarter bulk discounts to encourage handpiece purchases, potentially inflating reported revenue signals. The complaint also points to weaker-than-expected unit handpiece sales and excess inventory held by customers. These are allegations, and the company’s liability has not been established. Kahn Swick & Foti securities-fraud announcement
• Negative Sentiment: The legal action creates potential costs, management distraction, and continued uncertainty around PROCEPT’s sales practices, inventory levels, and the sustainability of its growth. The concentration of similar investor-alert releases may keep attention on the lawsuit even though the announcements do not represent new operating results or a new company disclosure. Glancy Prongay Wolke securities-fraud deadline alert

PROCEPT BioRobotics Stock Performance

NASDAQ:PRCT opened at $21.60 on Wednesday. The company has a current ratio of 6.55, a quick ratio of 5.35 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $1.24 billion, a P/E ratio of -11.13 and a beta of 0.89. The firm has a 50-day moving average price of $20.36 and a two-hundred day moving average price of $24.06. PROCEPT BioRobotics has a twelve month low of $16.67 and a twelve month high of $42.43.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). The firm had revenue of $94.50 million during the quarter, compared to analyst estimates of $92.77 million. PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The business’s quarterly revenue was up 19.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.35) EPS. As a group, research analysts expect that PROCEPT BioRobotics will post -1.67 earnings per share for the current fiscal year.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.